GlassScriptPhysician profile
Andrew Pugliese
NPI 1942258314
$10,541.54
in general payments reported to CMS, 2019-2025
40 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 81% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $1,045 · 2021: $3,592 · 2022: $1,445 · 2023: $1,340 · 2024: $1,304 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,831.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $1,811.05 | 2021 | |
| Paratek Pharmaceuticals, INC. | $1,245.59 | 2019-2025 | Nuzyra |
| Viiv Healthcare Company | $1,062.22 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Takeda Pharmaceuticals U.S.A., INC. | $808.57 | 2020-2024 | Cuvitru |
| Pfizer INC. | $728.12 | 2021-2025 | |
| Gilead Sciences, INC. | $651.49 | 2019-2025 | |
| Melinta Therapeutics, LLC | $557.92 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Cumberland Pharmaceuticals, INC. | $489.19 | 2019-2025 | Vibativ |
| Abbvie INC. | $425.60 | 2021-2025 | |
| Csl Behring | $322.65 | 2019-2025 | Hizentra |
| Octapharma USA, INC. | $292.11 | 2020-2022 | |
| Janssen Biotech, INC. | $223.44 | 2019-2023 | Symtuza |
| Insmed, INC. | $216.79 | 2020-2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $209.18 | 2019-2023 | Cresemba |
| Merck Sharp & Dohme LLC | $198.76 | 2020-2025 | Dificid, Zerbaxa, Pifeltro |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pugliese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.